1
|
Doignon I, Fayol O, Dellis O. Improvement of the rituximab-induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines. Oncotarget 2019; 10:4466-4478. [PMID: 31320998 PMCID: PMC6633894 DOI: 10.18632/oncotarget.27063] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2018] [Accepted: 06/19/2019] [Indexed: 11/25/2022] Open
Abstract
Mantle Cell Lymphoma (MCL) is one of the worst lymphomas with a median overall survival of 3 to 4 years. Even if the use of rituximab was a great step in therapy, patients commonly develop resistance and relapse. New therapies or complement of existing therapies should be developed. Using spectrofluorimetry, we found that the resting cytosolic Ca2+ ion concentration [Ca2+]cyt of MCL patients cells and MCL cell lines was increased. This increase is correlated with a larger store-operated calcium entry (SOCE) amplitude which is responsible for the Ca2+ ions influx. Furthermore, using a SOCE potentiating agent, we demonstrated that in the MCL Rec-1 cell line, the SOCE is already activated in resting conditions. Interestingly, this potentiating agent alone, by disturbing the SOCE, induced the apoptosis of Rec-1 cells with the same efficacy than rituximab. The use of the potentiating agent in addition to rituximab strengthens the rituximab-induced apoptosis of rituximab-sensitive Granta-519 and Rec-1 cells. However, this potentiating agent cannot convert the Jeko-1 rituximab-resistant to a rituximab-sensitive cell line. Our results confirm that the use of compound acting on the Ca2+ homeostasis could be a new target of interest in complement to existing therapies.
Collapse
Affiliation(s)
- Isabelle Doignon
- Interactions Cellulaires et Physiopathologie Hépatique, INSERM UMR-S 1174, Paris, France.,Université Paris-Sud, Université Paris Saclay, Paris, France
| | - Olivier Fayol
- Interactions Cellulaires et Physiopathologie Hépatique, INSERM UMR-S 1174, Paris, France.,Université Paris-Sud, Université Paris Saclay, Paris, France
| | - Olivier Dellis
- Interactions Cellulaires et Physiopathologie Hépatique, INSERM UMR-S 1174, Paris, France.,Université Paris-Sud, Université Paris Saclay, Paris, France
| |
Collapse
|
2
|
Gilbar PJ, Mutsando H, Richmond JP, Middleton RB. Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient. Int J Hematol Oncol 2016; 5:59-62. [PMID: 30302204 DOI: 10.2217/ijh-2016-0005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 07/18/2016] [Indexed: 11/21/2022] Open
Abstract
Limited data are available on the treatment of older adults with cancer. Comorbidities may preclude the administration of effective therapies, particularly in the extreme elderly. Comprehensive geriatric assessment can identify specific weaknesses of the patient and predict unexpected toxicities, thus enabling an optimized treatment strategy in this population. We report a case of the successful management of a 99-year-old female lymphoma patient with a strong wish for active treatment to improve quality of life and prolong survival past her 100th birthday. This case demonstrates that cancer treatment in the extreme elderly is possible and highlights the need for a formalized treatment plan based on geriatric assessment, frank discussion with patients and families, and defined goals of therapy.
Collapse
Affiliation(s)
- Peter J Gilbar
- Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia
| | - Howard Mutsando
- Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia
| | - Joshua P Richmond
- Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,School of Medicine, University of Queensland, Toowoomba Hospital, Toowoomba, QLD 4350, Australia
| | - Ronald B Middleton
- Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia.,Cancer & Palliative Care Services, Toowoomba Hospital, Toowoomba, QLD 4350, Australia
| |
Collapse
|
3
|
Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016; 174:255-63. [DOI: 10.1111/bjh.14049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 01/22/2016] [Indexed: 12/19/2022]
Affiliation(s)
| | - Emanuele Zucca
- IOSI (Istituto Oncologico della Svizzera Italiana); Bellinzona Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Ulrich Mey
- Kantonsspital Graubünden; Chur Switzerland
| |
Collapse
|
4
|
Vacher P, Vacher AM, Pineau R, Latour S, Soubeyran I, Pangault C, Tarte K, Soubeyran P, Ducret T, Bresson-Bepoldin L. Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. THE JOURNAL OF IMMUNOLOGY 2015. [PMID: 26202984 DOI: 10.4049/jimmunol.1402942] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The anti-CD20 mAb, rituximab, is routinely used to treat B cell malignancies. However, a majority of patients relapse. An improvement in the complete response was obtained by combining rituximab with chemotherapy, at the cost of increased toxicity. We reported that rituximab induced the colocalization of both the Orai1 Ca(2+) release-activated Ca(2+) channel (CRAC) and the endoplasmic reticulum Ca(2+) sensor stromal interaction molecule 1 with CD20 and CD95 into a cluster, eliciting a polarized store-operated Ca(2+) entry (SOCE). We observed that blocking this Ca(2+) entry with downregulation of Orai1, pharmacological inhibitors, or reducing calcemia with hypocalcemic drugs sensitized human B lymphoma cell lines and primary human lymphoma cells to rituximab-induced apoptosis in vitro, and improved the antitumoral effect of rituximab in xenografted mice. This revealed that Ca(2+) entry exerted a negative feedback loop on rituximab-induced apoptosis, suggesting that associating CRAC channel inhibitors or hypocalcemic agents with rituximab may improve the treatment of patients with B cell malignancies. The calcium-dependent proteins involved in this process appear to vary according to the B lymphoma cell type, suggesting that CRAC-channel targeting is likely to be more efficient than calcium-dependent protein targeting.
Collapse
Affiliation(s)
- Pierre Vacher
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France;
| | - Anne-Marie Vacher
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France
| | - Raphael Pineau
- Animalerie Mutualisée, Université de Bordeaux, F33400 Talence, France
| | - Simon Latour
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France
| | - Isabelle Soubeyran
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France
| | - Celine Pangault
- INSERM, Unité Mixte de Recherche 917, F-35043 Rennes, France; Université de Rennes 1, F-35043 Rennes, France; Centre Hospitalier Universitaire Pontchaillou, F-35033 Rennes, France
| | - Karin Tarte
- INSERM, Unité Mixte de Recherche 917, F-35043 Rennes, France; Université de Rennes 1, F-35043 Rennes, France; Centre Hospitalier Universitaire Pontchaillou, F-35033 Rennes, France
| | - Pierre Soubeyran
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France
| | - Thomas Ducret
- Université de Bordeaux, F-33076 Bordeaux Cedex, France; Centre de Recherche Cardio-Thoracique de Bordeaux, F-33076 Bordeaux Cedex, France; and INSERM, U1045, F-33076 Bordeaux Cedex, France
| | - Laurence Bresson-Bepoldin
- Institut Bergonié, Centre de Lutte contre le Cancer, F-33076 Bordeaux Cedex, France; Université de Bordeaux, F-33076 Bordeaux Cedex, France; INSERM U916 Validation et Identification de Nouvelles Cibles en Oncologie, F-33076 Bordeaux Cedex, France;
| |
Collapse
|
5
|
Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82. [PMID: 24881010 DOI: 10.1016/j.ejim.2014.05.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Revised: 03/14/2014] [Accepted: 05/01/2014] [Indexed: 11/23/2022]
Abstract
BACKGROUND Few data on patterns of care and outcomes are available for elderly patients with diffuse large B-cell lymphoma (DLBCL) outside of clinical trials. METHODS We identified patients with DLBCL older than 60 years from a regional cancer registry between 2000 and 2010. Based on registry data and chart review, 128 patients from the oncology network of Eastern Switzerland were analysed for patient characteristics, treatment and outcomes of DLBCL. Three age groups were compared: 60-69, 70-79 and over 80 years old. RESULTS Median age was 73 years (range: 60 to 95 years). 52/121 treated patients received 6 cycles of R-CHOP/CHOP, of those 30 (58%), 18 (35%) and 4 (7%) patients were 60-69 years, 70-79 years or older than 80 years respectively, with a significant difference by age group, p=0.001. Median OS of patients 60-69, 70-79, and 80 years and older receiving 6 cycles of R-CHOP/CHOP were: 54 months, 31 months and 24 months respectively. In comparison, patients receiving other than 6 cycles of R-CHOP/CHOP treatment regimens had a median OS of 22 months, 17 months and 6 months, respectively. In the multivariable analysis other than 6 cycles of R-CHOP/CHOP were significantly associated with poor survival. The risk of dying increased by a mean of 6% for each year of age from age 60 years onwards. CONCLUSION In conclusion, treatment regimens other than 6 cycles of R-CHOP/CHOP were significant predictors for survival in our oncology network. The possibility of using R-CHOP treatment regimen should be seriously considered in elderly patients with DLBCL.
Collapse
Affiliation(s)
- S Diem
- Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland.
| | - S Ess
- Swiss Cancer League, Flurhofstrasse 7, 9000 St. Gallen, Switzerland
| | - Th Cerny
- Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland
| | - M Früh
- Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland
| | - F Hitz
- Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland
| |
Collapse
|
6
|
Laurent M, Paillaud E, Tournigand C, Caillet P, Le Thuaut A, Lagrange JL, Beauchet O, Vincent H, Carvahlo-Verlinde M, Culine S, Bastuji-Garin S, Canouï-Poitrine F. Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist 2014; 19:275-82. [PMID: 24569945 DOI: 10.1634/theoncologist.2013-0351] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE To assess solid cancer treatment feasibility in older patients. METHODS Between 2007 and 2010, 385 consecutive elderly patients (mean age: 78.9 ± 5.4 years; 47.8% males) with solid malignancies referred to two geriatric oncology clinics were included prospectively. We recorded feasibility of first-line chemotherapy (planned number of cycles in patients without metastases and three to six cycles depending on tumor site in patients with metastases), surgery (patient alive 30 days after successfully performed planned surgical procedure), radiotherapy (planned dose delivered), and hormonal therapy (planned drug dose given), and we recorded overall 1-year survival. RESULTS Main tumor sites were colorectal (28.6%), breast (23.1%), and prostate (10.9%), and 47% of patients had metastases. Planned cancer treatment was feasible in 65.7% of patients with metastases; this proportion was 59.0% for chemotherapy, 82.6% for surgery, 100% for radiotherapy, and 85.2% for hormonal therapy. In the group without metastases, feasibility proportions were 86.8% overall, 72.4% for chemotherapy, 95.7% for surgery, 96.4% for radiotherapy, and 97.9% for hormonal therapy. Factors independently associated with chemotherapy feasibility were good functional status defined as Eastern Cooperative Oncology Group performance status <2 (p < .0001) or activities of daily living >5 (p = .01), normal mobility defined as no difficulty walking (p = .01) or no fall risk (p = .007), and higher creatinine clearance (p = .04). CONCLUSION Feasibility rates were considerably lower for chemotherapy than for surgery, radiotherapy, and hormonal therapy. Therefore, utilization of limited geriatric oncology resources may be optimized by preferential referral of elderly cancer patients initially considered for chemotherapy to geriatric oncology clinics.
Collapse
Affiliation(s)
- Marie Laurent
- Université Paris Est, Faculté de Médecine, LIC, EA4393 Créteil, France; Département de Médecine Interne et Gériatrie, Unité de Coordination d'Onco-Gériatrie (UCOG-Sud Val de Marne), Service d'Oncologie Médicale, Service de Santé Publique, Unité de Recherche Clinique, Service de Radiothérapie, and Service de Pharmacie, AP-HP, Hôpital Henri-Mondor, Créteil, France; Centre hospitalier universitaire, Département de Neuroscience, Division Médecine gériatrique Angers, France; AP-HP Hôpital Paul Brousse, Service de soins de suite polyvalents, Villejuif, France; AP-HP, Hôpital Saint-Louis, Service d'Oncologie Médicale, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|